StockData

Kazia Therapeutics vs Senti Biosciences

KZIA and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KZIA and SNTI compare

Senti Biosciences scores higher on the StockData Score (4 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKZIASNTI
Size and price
Market cap–$3.0M
Share price$5.31$0.097
Change, 1 year−15.3%−94.0%
Change, 5 years−98.9%−99.9%
Beta (5Y)4.083.17
Employees14–
StockData Score
Total score14 (better)
Valuation score00
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Growth
Revenue growth (TTM)−98.2%–
Profitability
Net margin−49291%–
Return on equity–−466%
Financial health
Current ratio2.87 (better)0.83
Altman Z-score–−21.38
Piotroski F-score22
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.45%18.6%
Held by insiders0.29%–
Superinvestors holding1–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.